3-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol | 1070878-63-5

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: 3-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol
• 英文别名: Flortanidazole；3-fluoro-2-[4-[(2-nitroimidazol-1-yl)methyl]triazol-1-yl]propan-1-ol
• CAS: 1070878-63-5
• 化学式: C₉H₁₁FN₆O₃
• 分子量: 270.223
• InChiKey: ZSSPATINHRVRTN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  115
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  N-propargyl-2-nitroimidazole 在 copper(ll) sulfate pentahydrate 、 sodium ascorbate 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 、 叔丁醇 为溶剂， 反应 2.0h， 生成 3-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol
  参考文献：
  名称：

  Continuous Flow Microfluidic Chemistry: Synthesis of [18F]-3-Fluoro-2-(4-((2-nitro-1H-Imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)Propan-1-ol, [18F]F-HX4, A Potent Hypoxia Agent

  摘要：

  The microfluidic synthesis of the promising hypoxia imaging agent [F-18]-3-fluoro-2-(4-((2-nitro-IH-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol, [F-18]F-HX4, was successfully accomplished using a commercial microfluidic system. A decay corrected radiochemical yield of 48 4% (n=4) and radiochemical purity of >= 98% was obtained. The total reaction time including the HPLC purification was 40 min.

  DOI：

  10.3987/com-15-s(t)28

文献信息

• Nitro-Imidazole Hypoxia Imaging Agents
  申请人：Kolb Hartmuth C.

  公开号：US20090010846A1

  公开（公告）日：2009-01-08

  The present invention relates to novel radioactively labeled bioreducible tracers of Formula I useful for detecting hypoxic tumors or ischemic tissue in vivo. In one embodiment, the tracers consist of a 2-nitroimidazole moiety, a triazole, metabolically stable linker with pharmacokinetics enhancing substituents, and a radioisotope. The preferred in vivo imaging modality is positron emission tomography.

  本发明涉及一种新型的放射性标记的生物可还原示踪剂，其化学式为I，用于体内检测低氧肿瘤或缺血组织。在一个实施例中，示踪剂由2-硝基咪唑基团、三唑、代谢稳定的连接物质和药代动力学增强取代基组成，并带有一个放射性同位素。首选的体内成像技术是正电子发射断层扫描。
• Nitro-imidazole hypoxia imaging agent
  申请人：Siemens Medical Solutions USA, Inc.

  公开号：US07977361B2

  公开（公告）日：2011-07-12

  The present invention relates to novel radioactively labeled bioreducible tracers of Formula I useful for detecting hypoxic tumors or ischemic tissue in vivo. In one embodiment, the tracers consist of a 2-nitroimidazole moiety, a triazole, metabolically stable linker with pharmacokinetics enhancing substituents, and a radioisotope. The preferred in vivo imaging modality is positron emission tomography.

  本发明涉及一种新型放射性标记的生物还原示踪剂，其化学式为I，可用于体内检测缺氧肿瘤或缺血组织。在其中一种实施方式中，示踪剂由2-硝基咪唑基团、三唑基团、代谢稳定的连接剂和药代动力学增强取代基组成。首选的体内成像模式为正电子发射断层扫描。
• Nitro-imidazole hypoxia imaging agents
  申请人：Siemens Medical Solutions USA, Inc.

  公开号：US07807394B2

  公开（公告）日：2010-10-05

  The present invention relates to novel radioactively labeled bioreducible tracers of Formula I useful for detecting hypoxic tumors or ischemic tissue in vivo. In one embodiment, the tracers consist of a 2-nitroimidazole moiety, a triazole, metabolically stable linker with pharmacokinetics enhancing substituents, and a radioisotope. The preferred in vivo imaging modality is positron emission tomography.

  本发明涉及一种新型放射性标记的生物还原示踪剂I式，用于体内检测缺氧肿瘤或缺血组织。在一种实施方式中，示踪剂由2-硝基咪唑基团、三唑、代谢稳定的连接剂、药代动力学增强取代基和放射性同位素组成。首选的体内成像方式是正电子发射断层扫描。
• Compounds And Methods For Selective Imaging And/Or Ablation
  申请人：Auckland Uniservices Limited

  公开号：US20150010474A1

  公开（公告）日：2015-01-08

  The invention relates generally to compounds and methods for imaging and/or selective ablation of nitroreductase-expressing cells and/or biological agents. More particularly, although not exclusively, the invention provides compounds that are selectively metabolised by bacterial nitroreductases and are substantially insensitive to metabolism under oxic or hypoxic conditions by human nitroreductase enzymes.

  本发明涉及化合物和方法，用于成像和/或选择性消融硝基还原酶表达的细胞和/或生物制剂。更具体地说，虽然不仅限于此，本发明提供的化合物被细菌硝基还原酶选择性代谢，且在人类硝基还原酶酶下氧化或缺氧条件下代谢相对不敏感。
• Nitro-Imidazole Hypoxia Imaging Agent
  申请人：Collier Thomas Lee

  公开号：US20110002850A1

  公开（公告）日：2011-01-06

  The present invention relates to novel radioactively labeled bioreducible tracers of Formula I useful for detecting hypoxic tumors or ischemic tissue in vivo. In one embodiment, the tracers consist of a 2-nitroimidazole moiety, a triazole, metabolically stable linker with pharmacokinetics enhancing substituents, and a radioisotope. The preferred in vivo imaging modality is positron emission tomography.

  本发明涉及一种新型的放射性标记的生物还原追踪剂I式，用于检测体内缺氧肿瘤或缺血组织。在一种实施方案中，追踪剂由2-硝基咪唑基团、三唑基团、代谢稳定的连接剂以及药代动力学增强取代基和放射性同位素组成。首选的体内成像方式是正电子发射断层扫描。